San Antonio Breast Cancer Symposium | Conference

Continuous Low-Dose Ribociclib Both Safe and Active in Advanced Breast Cancer

December 16th 2016

A continuous low-dose of ribociclib demonstrated both preliminary activity and an acceptable safety profile when compared with an intermittent dose of ribociclib when combined with fulvestrant in the treatment of postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Carboplatin Response Rate Not Superior to Docetaxel in BRCA1 Methylated or Silenced TNBC

December 16th 2016

Testing for BRCA1 methylation or mRNA silencing did not predict a better response to carboplatin over docetaxel in patients with advanced triple-negative or BRCA1/2 breast cancer.

Dr. Prat on HER2-Enriched Subtype as Strong Predictor of HER2-Targeted Treatment

December 15th 2016

Aleix Prat, MD, PhD, head of the Department of Medical Oncology, the August Pi i Sunyer Biomedical Research Institute, discusses the results of the open-label PAMELA trial, in which the HER2-enriched subtype predicted pathologic complete response to targeted treatment in patients with HER2-positive, hormone receptor-positive breast cancer.

Dr. Rimawi on Neoadjuvant Estrogen Deprivation Therapy in HER2+ Breast Cancer

December 15th 2016

Mothaffar F. Rimawi, MD, associate professor and medical director at the Lester and Sue Smith Breast Center at the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, discusses the findings of the NSABP B-52 trial, which explored the addition of neoadjuvant estrogen deprivation therapy to docetaxel and carboplatin plus the HER2 inhibitors trastuzumab (Herceptin) and pertuzumab (Perjeta) as treatment for patients with HER2-positive breast cancer.

Dr. Dieras on Combo of Veliparib and Chemotherapy in BRCA1/2-Mutant Breast Cancer

December 13th 2016

Véronique Diéras, MD, Department of Clinical Research, Institut Curie Paris & Saint Cloud, discusses results of a phase II trial exploring the combination of the PARP inhibitor veliparib with chemotherapy in patients with BRCA1/2-mutant breast cancer.

Brock Schroeder Discusses BCI Findings in ER+ Breast Cancer

December 13th 2016

Brock Schroeder, PhD, senior director, Medical and Scientific Affairs at bioTheranostics, discusses findings regarding the Breast Cancer Index in predicting patients with estrogen receptor (ER)-positive breast cancer at high risk of recurrence.

Dr. Alvarez on Updated Findings With Eribulin in Patients With HER2- Breast Cancer

December 13th 2016

Ricardo H. Alvarez, MD, MSc, director of Cancer Research, breast medical oncologist, Southeastern Regional Medical Center, Cancer Treatment Centers of America, discusses updated findings regarding the mechanism of action with eribulin mesylate (Halaven) and how it impacts patients with HER2-negative breast cancer.

Dr. Nangia on the SCALP Trial for Early-Stage Breast Cancer

December 12th 2016

Julie R. Nangia, MD, assistant professor, Breast Center-Clinic, faculty senator, Baylor College of Medicine, discusses the results of the Scalp Cooling Alopecia Prevention trial (SCALP) for patients with early-stage breast cancer.

Pembrolizumab Shows Durable Responses in Heavily Pretreated TNBC

December 10th 2016

Treatment with pembrolizumab continued to show a consistent durable benefit with an additional year of follow-up for heavily pretreated patients with recurrent PD-L1-positive metastatic triple-negative breast cancer.

Dr. Burris on Updated MONALEESA-2 Trial Results for HR+ Breast Cancer

December 10th 2016

Howard A. "Skip" Burris, MD, president of Clinical Operations and chief medical officer at Sarah Cannon Research Institute, discusses updated findings from the MONALEESA-2 trial, which explored first-line treatment with ribociclib plus letrozole in patients with hormone receptor (HR)-positive, HER2-negative breast cancer.

Dr. Tolaney on Pembrolizumab Plus Eribulin in TNBC

December 10th 2016

Sara M. Tolaney, MD, MPH, associate director, Clinical Research, Breast Oncology, Susan F. Smith Center for Women's Cancers, senior physician, instructor in Medicine, Harvard Medical School, discusses a phase Ib/II trial exploring eribulin mesylate (Halaven) in combination with pembrolizumab (Keytruda) in patients with metastatic triple-negative breast cancer (TNBC).

Pembrolizumab/Eribulin Combo Shows Promise for TNBC

December 10th 2016

The combination of pembrolizumab and eribulin demonstrated a 33.3% objective response rate for patients with metastatic triple-negative breast cancer who received 0 to 2 prior lines of therapy.

IBM's Watson Achieves High Concordance in Tumor Board Test

December 10th 2016

The artificial intelligence computer program Watson for Oncology (WFO) achieved a high degree of concordance with tumor board recommendations in a double-blinded validation study in Bengaluru, India, according to results presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).

AI Therapy May Pose Cardiovascular Risk for Breast Cancer Survivors

December 10th 2016

Aromatase inhibitor (AI) therapy may pose a risk of cardiovascular disease to postmenopausal women with early-stage breast cancer, raising the possibility of a long-term complication in an era of growing survivorship when patients are treated with estrogen-targeting drugs for years.

Women With Menopausal Symptoms Less Likely to Adhere to Breast Cancer Prevention Treatment

December 10th 2016

Women who are experiencing symptoms of menopause are less likely to adhere to treatment, according to findings presented at the 2016 San Antonio Breast Cancer Symposium.

Ribociclib Shows Consistent Benefit in Advanced Breast Cancer Subgroups

December 10th 2016

A subgroup analysis of the randomized MONALEESA-2 trial showed that patients with advanced HR-positive, HER2-negative breast cancer, and visceral metastases obtained a significant benefit from treatment with the CDK4/6 inhibitor ribociclib combined with letrozole.

Sacituzumab Govitecan Elicits Durable Responses for Pretreated TNBC

December 10th 2016

Treatment with sacituzumab govitecan was well-tolerated and induced durable responses, some lasting longer than 1 year, for heavily pretreated patients with metastatic triple-negative breast cancer.

More Evidence That Scalp Cooling Devices Work, Especially During Taxane-Based Chemotherapy

December 9th 2016

Findings from the first prospective, randomized clinical trial to evaluate modern scalp-cooling demonstrate that the system is safe and effective in reducing hair loss in women being treated with chemotherapy for their breast cancer, especially for those on taxane-based regimens.

Prophylactic Regimen Reduces Neratinib-Related Diarrhea in HER2+ Breast Cancer

December 9th 2016

Prophylactic treatment with the combination of loperamide and budesonide reduced the rate of grade ≥3 diarrhea associated with neratinib to 15% compared with 39.9% observed in the ExteNET trial.

New Mechanism of Action Results Renew Interest in Eribulin

December 9th 2016

There has been renewed interest in eribulin mesylate following its FDA approval for advanced or unresectable liposarcoma and with the introduction of a growing body of preclinical work suggesting the agent has a novel anti–mesenchymal mechanism of action.